Gland Pharma Q1 FY27 Result: Net Profit Surges 47% YoY; CDMO Business Drives 50% of Revenues Gland Pharma reported a strong financial performance for the April-June quarter (Q1 FY27), with consolidated net profit rising 47% year-on-year to ₹317 crore. This marks a significant increase from the ₹215 crore recorded in the same period of the previous fiscal year. The company’s revenue from operations grew 19.5% to ₹1,800 crore, driven by robust performance in key markets. The US market was the primary growth driver, with revenue increasing 32% YoY to ₹981 crore. Europe also contributed to the growth, recording a 20% rise to ₹395 crore. Meanwhile, the India business saw a 12% year-on-year increase to ₹67 crore, while the rest of the world segment grew 2% to ₹304 crore. However, revenue from Canada, Australia, and New Zealand declined 28% YoY to ₹53 crore. The company’s operating profit, or EBITDA, surged 33% to ₹489 crore, compared to ₹368 crore in the same period last year. The EBITDA margin expanded to 27.16% from 24.44% in Q1 FY26, reflecting improved efficiency. Research and development expenses totaled ₹77 crore, representing 4% of consolidated revenue, with a focus on complex product development and regulatory filings. Gland Pharma launched four new molecules in the US during the quarter, including multi-vitamin and leucovorin calcium. The company also filed three ANDAs and received seven approvals. As of Q1 FY27, the firm has submitted 389 ANDA filings in the US, with 342 approvals and 47 pending. The CDMO business, which provides contract development and manufacturing services, contributed 50% of total revenues and recorded a 20% YoY growth.#gland_pharma #srinivas_sadu #us_market #cdmo_business #global_pharmaceutical_company
Gland Pharma Q1 net surges 47% to ₹317 cr on higher revenue Gland Pharma, a major player in the injectable generic drug market, reported a significant rise in its consolidated net profit for the June quarter, surging 47% year-on-year to ₹317 crore. This growth was fueled by a 20% increase in revenue from operations to ₹1,800.3 crore. However, on a sequential basis, the company’s net profit dipped by 14%, while revenue rose marginally by 3%. The surge in profitability was attributed to recent product launches from its Contract Development and Manufacturing Organization (CDMO) portfolio and robust customer demand. Executive Chairman Srinivas Sadu highlighted the company’s strategic focus on investing in differentiated technologies and expanding capacity to build a strong CDMO pipeline. These initiatives are aimed at enhancing its position in the global pharmaceutical landscape. Revenue from the U.S., Gland Pharma’s key market, grew by 32% YoY to ₹981 crore, though it remained flat sequentially. In contrast, revenue from Canada, Australia, and New Zealand—its other core markets—declined 28% YoY to ₹53.4 crore, with a 9% sequential drop. This divergence in performance underscores the varying dynamics of the company’s regional operations. A major development in the quarter was Gland Pharma’s announcement of a strategic manufacturing and supply agreement with a leading global pharmaceutical company. This partnership involves technology transfer, manufacturing, and supply of sterile injectable products for global markets. The collaboration positions Gland Pharma as an integrated end-to-end partner, supporting products across various stages of their lifecycle, including both commercially available and pipeline products.#us #australia #canada #gland_pharma #srinivas_sadu
